mice
immun
plasmid
dna
encod
ebola
gp
trimer
virionassoci
involv
cellular
follow
boost
antibodi
respons
surrog
measur
use
enzymelink
immunosorb
assay
elisa
dna
vaccin
titr
modest
increas
boost
fig
contrast
vaccin
gave
rise
lower
antibodi
titr
gener
rapidli
investig
whether
immun
adenovir
vector
alon
might
protect
ebola
viru
infect
altern
immun
schedul
macaqu
develop
comparison
previou
dnaadv
protocol
fig
middl
bottom
panel
compar
top
panel
cynomolgu
macaqu
immun
follow
boost
week
later
fig
middl
panel
one
week
boost
anim
challeng
either
low
plaqueform
unit
pfu
high
pfu
dose
isol
ebola
viru
zair
dose
uniformli
fatal
day
afterward
salineinject
control
anim
contrast
immun
monkey
n
complet
protect
confirm
viral
load
fig
analysi
cellmedi
humor
immun
respons
reveal
signific
increas
tcell
respons
ebola
antigen
intracellular
cytokin
stain
interferon
ifn
seen
exposur
viru
contrast
control
anim
respons
seen
fig
similarli
antibodi
titr
viru
stimul
vaccin
anim
minim
increas
viral
challeng
fig
substanti
increas
observ
number
ebolaspecif
cell
time
data
shown
cellular
humor
immun
respons
therefor
associ
protect
second
adenovir
immun
substanti
increas
ebolaspecif
immun
respons
data
shown
rais
notion
primari
immun
suffici
confer
protect
address
possibl
singl
immun
given
anim
challeng
one
month
afterward
fig
bottom
panel
low
high
viral
challeng
dose
anim
complet
protect
infect
fig
case
chang
intracellular
respons
lymphocyt
consist
seen
data
shown
howev
ebolaspecif
tcell
respons
detect
intracellular
tumournecrosi
factor
tnf
respons
observ
challeng
induc
soon
thereaft
five
eight
anim
correl
protect
infect
fig
right
contrast
respons
detect
inocul
increas
challeng
fig
left
igg
antibodi
titr
readili
detect
time
inocul
also
associ
protect
fig
data
demonstr
singl
inject
acceler
vaccin
protect
longterm
surviv
ebola
nonhuman
primat
fig
ebola
viru
infect
character
rapid
onset
high
persontoperson
transmiss
signific
mortal
rate
mainstay
treatment
support
therapi
prevent
depend
contain
use
barrier
precaut
effect
protect
achiev
previous
primat
heterolog
dna
prime
adenovir
boost
strategi
immun
reli
abil
adenovir
boost
expand
primari
tcell
respons
induc
dna
vaccin
anim
prime
adv
vector
alon
robust
ebolavirusspecif
cellular
humor
immun
respons
rapidli
achiev
although
respons
second
inject
blunt
probabl
antivector
immun
explor
possibl
rapid
initi
immun
respons
may
nonetheless
confer
protect
outweigh
stronger
immun
respons
requir
addit
time
singl
immun
adenovir
vector
encod
ebola
viru
protein
suffici
confer
protect
lethal
challeng
within
four
week
respons
correl
cellular
humor
immun
respons
infect
although
antibodi
titr
correl
protect
respons
previou
studi
nonhuman
primat
suggest
passiv
transfer
antibodi
insuffici
provid
longlast
protect
ebola
rodent
studi
adapt
ebola
viru
passiv
transfer
adopt
transfer
cytotox
show
protect
given
infect
sensit
less
quantit
lymphoprolif
respons
correl
protect
previou
dnaadv
studi
respons
addit
antibodi
respons
induc
vaccin
present
studi
respons
observ
challeng
fact
respons
observ
challeng
either
protocol
wherea
respons
consist
seen
beforehand
suggest
respons
like
import
role
protect
nonhuman
primat
analysi
requir
assess
rel
import
cellular
humor
immun
respons
mechan
protect
approach
singl
vaccin
inject
adv
vector
relev
contain
treatment
ebola
viru
relat
outbreak
continu
emerg
central
vaccin
approach
prove
effect
human
find
rais
possibl
ring
vaccin
could
use
contain
outbreak
similar
smallpox
past
result
also
suggest
altern
strategi
vaccin
ebola
acut
pathogen
diseas
strategi
remain
immunolog
potent
respons
highli
durabl
may
still
use
prevent
vaccin
exampl
hospit
worker
contrast
singl
adenovir
vaccin
administr
may
better
use
acut
outbreak
also
possibl
altern
viral
vector
deriv
adenoviru
serotyp
poxviru
vector
might
use
boost
adv
type
vector
primari
immun
altern
adv
serotyp
also
help
overcom
immun
natur
adv
type
infect
could
potenti
reduc
vaccin
efficaci
popul
oneshot
vaccin
may
help
control
ebola
viru
outbreak
great
ape
popul
central
analog
singledos
adv
vector
immun
could
also
use
emerg
highli
lethal
infecti
pathogen
marburg
lassa
sar
coronaviru
prepar
describ
recombin
adenovir
vector
made
accord
previous
publish
dose
mice
nonhuman
primat
adenovir
vector
particl
compon
administ
anim
without
advers
effect
twenti
cynomolgu
macaqu
macaca
fasciculari
yr
old
weigh
kg
obtain
covanc
use
immun
challeng
experi
monkey
hous
singli
anaesthet
ketamin
obtain
blood
specimen
administ
vaccin
receiv
regular
enrich
accord
guid
care
use
laboratori
anim
dhew
number
nih
ebola
viru
challeng
end
experi
anim
maintain
maximum
contain
laboratori
fed
check
daili
dna
adenovir
vector
express
ebola
zair
glycoprotein
mayinga
strain
construct
describ
gene
express
control
cytomegaloviru
enhanc
promot
plasmid
mice
n
per
group
immun
intramuscularli
dna
pgp
andor
particl
adenoviru
dna
vaccin
perform
day
adenovir
boost
day
adenovir
inject
perform
day
sampl
collect
elisa
titr
indic
time
elisa
igg
titr
determin
use
plate
previous
specif
antigen
bind
detect
use
goat
antihuman
igg
h
l
horseradish
conjug
abtsperoxid
substrateind
polyvinyl
chlorid
elisa
plate
dynatech
coat
antigen
per
well
incub
overnight
incub
carri
room
temperatur
antigen
use
purifi
ebola
viru
mg
total
protein
inactiv
gamma
irradi
plate
wash
five
time
pb
contain
test
sera
dilut
halflog
concentr
allow
react
antigenco
well
min
wash
plate
five
time
goat
antimonkey
igg
whole
molecul
icn
biomed
conjug
horseradish
peroxidas
use
detect
antibodi
bound
igg
detect
acid
diammonium
salt
optic
densiti
determin
panel
normal
serum
run
time
assay
perform
cutoff
valu
posit
result
calcul
mean
optic
densiti
dilut
normal
sera
plu
standard
deviat
peripher
blood
mononuclear
cell
isol
cynomolgu
macaqu
wholeblood
sampl
separ
ficol
approxim
cell
stimul
rpmi
medium
gibco
h
antibodi
either
dmso
pool
peptid
span
ebola
gp
zair
mayinga
strain
open
read
frame
peptid
nucleotid
overlap
span
entir
ebola
glycoprotein
final
concentr
cell
fix
permeabl
fac
lyse
becton
dickinson
supplement
stain
mixtur
antibodi
lineag
marker
either
tnfapc
sampl
run
fac
calibur
analys
use
softwar
flowjo
posit
gate
lymphocyt
use
forward
versu
side
scatter
follow
gate
specif
popul
defin
posit
respect
cytokineposit
cell
defin
percentag
within
individu
lymphocyt
subset
least
event
analys
sampl
conduct
research
investig
adher
guid
care
use
laboratori
anim
prepar
institut
laboratori
anim
resourc
nation
research
council
facil
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
cynomolgu
macaqu
inject
intramuscularli
indic
time
fig
equal
mixtur
particl
viral
challeng
perform
inocul
anim
left
right
caudal
thigh
ml
viral
stock
contain
target
dose
either
pfu
ebola
viru
zair
speci
ten
week
fig
four
week
fig
initi
immun
actual
titr
confirm
plaqu
advers
effect
adenoviru
vaccin
observ
acut
ebola
viru
use
studi
origin
obtain
fatal
infect
human
former
zair
ref
collect
serum
blood
viral
load
elisa
titr
perform
previous
